Fc Effector Function (ADCC, ADCP, CDC) Evaluation Service for Veterinary (Pet) Antibody

Fc effector function evaluation service for veterinary antibody: optimizing your veterinary antibody's therapeutic power! Are you facing challenges in predicting in vivo efficacy, elucidating your antibody's mechanism of action, or selecting the most promising lead candidate for pet therapeutics? Creative Biolabs' Fc effector function evaluation service helps you precisely quantify the cytotoxic potential of your veterinary antibodies through robust, validated cell-based reporter assays and primary immune effector cells from relevant companion animal species.

Workflow

Our streamlined workflow is designed to provide robust and species-relevant data on antibody Fc-mediated immune functions in veterinary settings. Each step is tailored to support preclinical evaluation of therapeutic antibody candidates across canine, feline, and other veterinary models.

Antibody Fc Effector Function Evaluation Service Workflow. (Creative Biolabs Original). Fig 1. Pet Antibody Fc Effector Function Evaluation Service Workflow. (Creative Biolabs Original)

Project Consultation & Study Design We begin with an in-depth consultation to understand your therapeutic antibody's species, isotype, target, and intended function. Based on your goals, we customize an evaluation plan covering ADCC, ADCP, and/or CDC assays using appropriate effector and target cells.
Target Cell Preparation We generate or utilize client-supplied target cells expressing the antigen of interest. These can be species-specific primary cells or stable cell lines labeled with fluorescence or luciferase reporters to enable sensitive detection.
Effector Function Assay Setup
  • ADCC: We co-culture target cells with canine/feline NK cells or FcγR-expressing reporter cells.
  • ADCP: We incubate target cells with macrophages or monocytes to quantify phagocytic uptake.
  • CDC: We expose antibody-treated target cells to species-matched serum to assess complement-dependent lysis.
Data Analysis & Comprehensive Reporting Using flow cytometry, luminescence, or high-content imaging, we measure cell lysis, phagocytosis, and immune activation. Data are analyzed to determine EC50, percent activity, and comparative efficacy among candidates. You'll receive a detailed technical report with experimental setup, raw and analyzed data, assay validation metrics, and professional interpretation tailored for regulatory or internal development use.

Introduction

Creative Biolabs translates antibody binding into functional understanding. Our service provides you with critical, quantitative data on your veterinary antibody's ability to engage the immune system and eliminate target cells. This empowers you to de-risk candidates early, select leads with the highest therapeutic potential, and build a robust data package essential for downstream development and regulatory confidence. We specialize in tailoring these complex biological assays to the unique immunology of companion animals, ensuring the data you receive is not just accurate, but physiologically relevant to your ultimate goal: improving animal health.

Discover How We Can Help - Request a Consultation

  • Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC)
    ADCC is a critical immune mechanism where an antibody flags a target cell (e.g., a cancer cell or virally infected cell) for destruction. Immune cells, primarily Natural Killer (NK) cells, recognize the antibody's Fc region via their Fc receptors (e.g., FcγRIIIa). This engagement triggers the release of cytotoxic granules, leading to the lysis and death of the target cell. Evaluating ADCC is paramount for veterinary oncology antibodies and anti-viral therapies.
  • Antibody-Dependent Cellular Phagocytosis (ADCP)
    In ADCP, antibodies act as a bridge, opsonizing (coating) a target for engulfment by phagocytic immune cells like macrophages and monocytes. These phagocytes use their Fc receptors to bind the antibody-coated target, initiating internalization and subsequent destruction within the cell. This clearance mechanism is vital for removing pathogens, cellular debris, and malignant cells, making ADCP evaluation a key step in developing many classes of therapeutic antibodies for companion animals.
  • Complement-Dependent Cytotoxicity (CDC)
    CDC is an effector function mediated by the classical complement pathway. When certain antibody isotypes bind to a target cell surface, their Fc regions can recruit and bind the C1q protein. This initiates a powerful enzymatic cascade that culminates in the formation of the Membrane Attack Complex (MAC), which perforates the target cell membrane, causing rapid lysis. This potent killing mechanism is a desired attribute for antibodies targeting specific cell populations for depletion.

Fc-Effector Functions. (van der Horst, et al., 2020) (OA Literature)Fig 2. Monoclonal Antibody Structure and Mechanisms of Action.1,2

Why Choose Us?

  • Veterinary-Specific Focus
    We don't just adapt human assays; we build them for veterinary medicine. Our platforms utilize species-specific effector cells (canine, feline) and validated models, delivering physiologically relevant data that is more predictive of in vivo outcomes in companion animals.
  • Multi-Platform Flexibility
    Our state-of-the-art facility is equipped with multiple validated assay formats, from classic primary cell cytotoxicity assays to high-throughput, sensitive reporter gene platforms. This allows us to select and customize the optimal, most cost-effective approach for your specific antibody, target, and research question.
  • Decision-Driving Data Packages
    We deliver more than just a number. Our comprehensive reports provide clear, actionable insights into your antibody's functional profile. Published data has consistently shown that robust in vitro functional characterization is key to guiding lead optimization and building a compelling case for further development.

FAQs

1. Which assay (ADCC, ADCP, or CDC) is most important for my antibody?
The answer depends on your antibody's isotype (e.g., IgG1 vs. IgG4) and its intended therapeutic action. For instance, an antibody designed to kill cancer cells would prioritize ADCC, while one for clearing immune complexes might rely more on ADCP. We can help you determine the most relevant assays based on your project goals during a brief, no-obligation discussion.
2. Can you evaluate Fc-engineered antibodies with enhanced functions?
Absolutely. Our assays are highly sensitive and well-suited to quantify the impact of Fc engineering, such as afucosylation for enhanced ADCC. We can clearly demonstrate the potency improvement of your engineered variants compared to a wild-type control, providing the validation you need for your design strategy. We'd be happy to discuss how we can showcase your molecule's advantages.

Related Services

Achieve a complete functional profile of your veterinary antibody with our complementary services.

(Creative Biolabs Authorized)Fc Engineering

Optimize your antibody's effector functions or half-life through our rational design and protein engineering services.

(Creative Biolabs Authorized)Blocking & Neutralization Evaluation

Determine your antibody's ability to inhibit ligand-receptor binding or neutralize pathogen activity with our functional assays.

(Creative Biolabs Authorized)Internalization Evaluation

Quantify the rate and extent to which your antibody is internalized by target cells, a critical parameter for antibody-drug conjugates.

(Creative Biolabs Authorized)Cell Signaling Pathway Evaluation

Elucidate your antibody's mechanism of action by assessing its impact on specific intracellular signaling cascades.

(Creative Biolabs Authorized)Cell-based Function Evaluation

Access our comprehensive suite of assays to characterize the full biological activity profile of your therapeutic antibody candidates.

Partner with Creative Biolabs

Creative Biolabs provides a comprehensive, veterinary-focused suite of Fc effector function evaluation services. We deliver clear, decision-enabling data to accelerate your therapeutic antibody development pipeline, from initial discovery to preclinical validation.

Ready to move your project forward with confidence? Our scientific experts are standing by to design a study that meets your unique needs and goals. Contact our team to learn more about our customized solutions for your antibody Fc effector function evaluation project.

Contact Our Team for More Information and to Discuss Your Project.

References

  1. van der Horst, Hilma J et al. "Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies." Cancers vol. 12,10 3041. 19 Oct. 2020, https://doi.org/10.3390/cancers12103041
  2. Distributed under Open Access license CC BY 4.0, without modification.
Services

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.